LINNO is Tackling Antibody-based Therapeutics

Shape
COMPLEMENT SYSTEM DISORDERS AND HUMAN DISEASES

Complement System Disorders and Human Diseases

As the main component of the innate immune system, complement system provides an essential or even critical supplement to functionalities of the acquired immune system which is composed of antibodies, T and B cells in immune surveillance of invading pathogens and malfunctional cells. Complement system disorders, either caused by genetic mutations, environmental factors, or aging-associated degenerative cellular damages, can lead to serious chronic or life-threatening diseases such as hereditary angioedema (HAE), paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremia (aHUS), or age-related macular disease (AMD). Potential roles of uncontrolled complement activation have also been elucidated in ischemic reperfusion injuries and aging-related neurological degeneration such as Alzheimer’s diseases.

Linno Pharmaceuticals Inc. is committed to understanding the biological relevance of complement system disorders in the courses of disease occurrence and development, and to providing targeted treatment.

Shape
DRUG DELIVERY ACROSS BLOOD-BRAIN BARRIER (BBB)

Drug Delivery across Blood-brain Barrier (BBB)

Central nervous system (CNS) disorders including genetic metabolic diseases, stroke, age-related degenerative diseases, mental illness and brain tumors, represent a family of diseases that have significant unmet medical needs or lack of meaningful treatment options. Drug delivery across the BBB is one of the major hurdles in drug discovery research and development targeting the central nervous system. For biomacromolecules, such as fusion proteins or antibodies, receptor-mediated transmembrane transport has been well explored, such as using recombinant proteins or antibodies targeting CD71 (TfR1), CD98 (SLC3A2), CD221 (IGF1R) among others. Technical challenges include relatively low efficiency in BBB penetration, poor developability or manufacturability, or concerns about neurotoxicity.

At Linno Pharmaceuticals Inc., we are exploring one BBB-crossing process utilized by natural metabolites for targeted drug delivery to the central nervous system Nano Brain-Pass. Compared to technologies from peers, our approach enables safe and effective BBB-crossing drug delivery without much concerns about engineering-created developability or manufacturability issues.